In the time before COVID-19, many people would have been heading to the Bay Area in the US for AIDS2020 and to Mexico City for HIV2020. Now, both conferences are virtual. Read on for highlights and ways to navigate AIDS2020 Virtual, and stay tuned for other updates on HIV2020.

As in years past, AIDS2020 is offering the latest scientific breakthroughs on HIV, opportunities for advocates to come together to sharpen their agenda and new this year, a special day-long meeting devoted to COVID-19. The pre-conferences began today and there is a full agenda through July 10. Highlights Include:

• The latest global HIV estimates from UNAIDS.
• A survey of LGBTI+ people in 138 countries assessing the socioeconomic impact of COVID-19.
• New evidence on what may be the first adult with HIV achieving long-term HIV remission without a bone marrow transplant.
• Analysis of the safety and efficacy of the first long-acting injectable PrEP.

The satellites and regular conference sessions are only available to those who register for the conference. But, as in previous years, there will be a Global Village that’s free and open to the public, featuring networking zones, workshops and more.

Another complimentary offering is the final day of the conference—the July 10 special meeting on COVID-19, which will focus on developments in the research pipeline for SARS-CoV-2, policy analysis and lessons from the field. Click here for a free registration. And for more on the COVID-19 and intersections with HIV check out AVAC’s dedicated resources at www.avac.org/covid.

Navigating the Conference

• Check out the full program at the AIDS2020 website.
• HIV Prevention Roadmap – Click to download the roadmap, which can be sorted by timing, intervention or session type (poster, workshop, plenary or satellite).
• AVAC@AIDS 2020 – Click to download a summary of sessions, satellites and poster presentations from the AVAC team.
• Research Literacy Networking Zone Pop-Up Chats – Click to download the schedule of pop-up chats with researchers and advocates.

Tracking the News

• For highlights from the conference follow AVAC on Twitter and the conference hashtag, #AIDS2020.
• Go to aidsmap for their daily coverage of AIDS 2020.

Program Highlights

Note: sessions may be streamed at multiple times, some are also streamed live, and many sessions are available to download on demand. Times reflect Pacific Daylight Time (PDT).

• The Research Literacy Networking Zone (RLNZ) in the Global Village
• Towards an HIV Cure: Opening session & Advancing the HIV cure field and debunking myths and misconceptions
• Bringing PrEP Closer to Home: Why is now the time for differentiated PrEP?
• The Power of Peers: Training HIV prevention ambassadors to support PrEP use in their communities
• HIV Vaccine: The search goes on!
• One Year After ECHO: Integration in the Time of COVID
• Data-Driven Advocacy in 2020 and Beyond: Tools and tactics for civil society to define and win high-impact change in the HIV response
• Ending the HIV Epidemic: Optimism, realism and disparities
• How did they do it? What successful communities can teach all of us about making dramatic progress against HIV epidemics and what this means in the age of COVID
• Bound But Not Gagged: Resilience in the era of the global gag rule

Every Day During AIDS 2020 Virtual

Networking Zones Channel
AVAC’s Research Literacy Zone (RLZN) will connect you to resources offering a foundation in biomedical interventions, the clinical trial process, advocacy for the integration of sexual reproductive health with HIV prevention and treatment, and the impact of HIV and COVID-19 on each other. The RLZN will also feature a series of virtual conversation and Q&As with leading researchers and advocates on topics such as: the status and implications of HVTN 083 & 084— two trials looking at the antiretroviral cabotegravir as a long-acting injectable PrEP; the AMP trial testing a broadly neutralizing antibody (bNAb) expected to announce results later this year; the larger bNAb research agenda; the basics of stakeholder engagement in research; an introduction to HIV cure research and more. Download the schedule here.

Wednesday, July 1

07:00–08:30, Pre-Conference Channel 4
Towards an HIV Cure: Opening session & Advancing the HIV cure field and debunking myths and misconceptions. At this pre-conference session, join a moderated discussion on cure strategies in resource-limited settings, myths and misconceptions, changing attitudes and advances in research.

Monday, July 6

06:00–07:00, Satellite Channel 3; 23:00–24:00, Satellite Channel 4
Bringing PrEP Closer to Home: Why is now the time for differentiated PrEP? A move toward more community-based and telehealth models have accelerated during COVID-19. Join this session Hear perspectives from providers, PrEP users, ministry of health, and global normative agencies and to discuss why differentiated service delivery DSD will be essential to significantly increase PrEPuptake by the end of 2020 and beyond!

05:00-06:00, Workshop Channel 2
The Power of Peers: Training HIV prevention ambassadors to support PrEP use in their communities. Priority populations such as adolescent girls and young women, men who have sex with men and other, must be offered meaningful ways to engage with peer support and effective advocacy in the context of rising community awareness to take PrEP and use it for as long as they need it. This workshop takes participants through the HIV Prevention Ambassador Training and learn how it boosts the impact of existing PrEP programs.

Tuesday, July 7

09:00-10:00, Satellite Channel 2; 12:00-13:00, Satellite Channel 3
HIV Vaccine: The search goes on! Despite life-saving advances in biomedical an HIV vaccine remains a necessity to finally end the epidemic. In this satellite, The Global HIV Vaccine Enterprise, NIH/HVTN/HPTN, with the participation of the South African Medical Research Council, IAVI, EU consortiums and AVAC are putting a spotlight on the breadth of ongoing research, and the role of funders, product developers, researchers and communities in sustaining HIV vaccine development.

Wednesday, July 8

06:00-07:00, Satellite Channel 2

One Year After ECHO: Integration in the Time of COVID. Results from the Evidence for Contraceptive Options and HIV Outcomes trial reflected the impact siloed services for family planning (FP), sexual and reproductive health, and HIV have on women’s health. The COVID-19 pandemic has only raised the urgency. This session looks at gains made in FP/HIV integration since the ECHO trial results; how COVID-19 is impacting the effort; and implications for the future. And check out our video series, One Expert, One Question, One Minute! Produced by AVAC and FP2020. Experts from all around the world share what we need to do for successful HIV/FP integration.

05:00–06:00, Workshop Channel 1
Data-Driven Advocacy in 2020 and Beyond: Tools and tactics for civil society to define and win high-impact change in the HIV response. Activists have marked recent wins using data strategically in campaigns. This session will explore case studies in East and Southern Africa and address the common barriers for civil society to deploy data effectively, such as missing or poor-quality data and lack of access.

Thursday July 9

08:00, IAS Networking Booth
Join a conversation with cure advocates on “what do you want to know about cure?” IAS/AVAC Advocacy-for-Cure Fellows Philister Adhiambo from Kenya Medical Research Institute (KMRI) , Owen Mulenga from (MUHJU), Josephine Nabukenya from the Treatment Advocacy and Literacy Campaign will answer your questions.

On Demand-Only Sessions

Symposia and Bridging Session, On-Demand Channel
Ending the HIV Epidemic: Optimism, realism and disparities. Join to hear four perspectives on where we are and where we should go as we aim to end the HIV epidemic around the world. Speakers will take four distinct perspectives, each speaking across geographies and populations.

Symposia and Bridging Session, On-Demand Channel
How did they do it? What successful communities can teach all of us about making dramatic progress against HIV epidemics and what this means in the age of COVID. Cities, regions and countries around the world have brought down HIV incidence and mortality. How did they do it? Last year, amfAR, AVAC and Friends of the Global Fight, in partnership with Kaiser Family Foundation, released a report, Translating Progress Into Success to End the AIDS Epidemic, looking at success stories. In this session, advocates and researchers from these case studies discuss how to apply the lessons they learned to advocacy and policy.

Symposia and Bridging Session, On-Demand Channel
Bound But Not Gagged: Resilience in the era of the global gag rule. Join top learn about the impact of the global gag rule and the domestic (US) gag rule on women and girls around the world, including key populations and how they have responded.

It’s an exciting and important time in HIV prevention research and advocacy. At AIDS 2020 Virtual, we can come together—COVID-19 be damned. As intrepid, committed advocates, we can push an HIV agenda forward to a future we clearly see—with many options for evidence-based prevention, well-funded research, and an integrated and equitable global response to the public health threats of today and tomorrow.

The stories are coming from Malawi, South Africa, Uganda, Zambia, Zimbabwe and elsewhere—people struggling to get treatment for chronic illness, failed attempts to refill ARVs and key prevention commodities, high numbers reporting they can’t get to the clinic, informal groups coming together to find and deliver medication. These are pictures of communities in lockdown from COVID-19, facing the consequences to public health.

This troubling news from advocates in sub-Saharan Africa has grave implications. According to a May 2020 analysis of multiple mathematic models by the HIV Modelling Consortium, COVID-related barriers to HIV treatment, care and prevention could result in 500,000 additional deaths from AIDS-related illnesses. The world has made tremendous progress against HIV. If we allow COVID-19 to set us back, we could lose more than a decade of these gains. As AVAC’s Mitchell Warren said, “We cannot play global health whack-a-mole and ignore other devastating diseases while we turn attention to COVID-19. HIV treatment and prevention interruption cannot be an acceptable result of COVID-19: in that model, even if we succeed against COVID-19, we fail against everything else.”

The good news is we know how to preserve the progress made: we have to urgently expand models for differentiated service delivery (DSD), and we have to do it right now. DSD puts clients at the center and adapts—tailoring HIV programs and services to reflect the preferences and expectations of various groups who need HIV prevention or treatment.

In Zimbabwe, a DSD program of the Batanai HIV & AIDS Service Organisation (BHASO) has succeeded with allowing health care workers to bring needed care and medicine to clients, instead of requiring clinic visits. The program is expanding and is exactly the kind of initiative that others should model.

DSD can mean people get their medications, learn about prevention options, find the counseling they need, and stay connected to care. DSD can mean individuals at risk of diseases such HIV or TB are engaging with healthcare that works for them.

AVAC has been expanding its advocacy for DSD, even before COVID-19 gripped the world. Why? Because tenaciously high incidence rates, a heartbreaking number of people lost to follow-up, and the millions of people who don’t know their status or are not virally suppressed can all be addressed with DSD. This means developing programs and services that clients and communities have helped to design, programs that offer a range of approaches, programs that support diverse needs.

Now we need DSD more than ever, so people can access the care, treatment and prevention they need in the midst of COVID-19 lockdowns and disruptions to the healthcare systems in their communities. The results of this new modeling escalate the urgency for widespread adoption of DSD approaches.

The modeling is detailed and the findings are drastic: five teams contributed to models looking at disruptions of three and six months and their impact on AIDS mortality and incidence. According to the findings, if services are disrupted for six months then additional deaths will range from 471,000-673,000 in the following year, which could bring the death toll from AIDS in 2021 to more than 900,000. Those figures “set back the clock” on the HIV epidemic to 2008, a year when the WHO reports 950,000 people died from AIDS in the region. And the heightened rates of loss of life are expected to last for years. Other predictions include reversed gains in mother-to-child transmission with a “drastic” rise of infections among children, up by 37 percent in Mozambique, 78 percent in Zimbabwe and 104 percent in Uganda, and adverse impacts on prevention efforts as well.

As advocates, we cannot allow these scenarios to come true. As UNAIDS executive director Winnie Byanyima says, “The COVID-19 pandemic must not be an excuse to divert investment from HIV. There is a risk that the hard-earned gains of the AIDS response will be sacrificed to the fight against COVID-19, but the right to health means that no one disease should be fought at the expense of the other.”

WHO leader, Dr. Tedros Adhanom Ghebreyesus, is also raising the alarm, “We must read this as a wake-up call to countries to identify ways to sustain all vital health services.”

Watch-dogging country governments to adapt HIV service delivery is vital to sustain and advance three decades of progress in HIV prevention and treatment. Countries must develop the capacity to deliver DSD rapidly and safely, while also pursuing the strongest and wisest course of action against COVID-19.

To get the job done:

• Give people options to choose where and when to access their ART and prevention, and make it easy for them to do so. No one size fits all.
• Governments and donors must establish models that revolve around the clients, not the health system.
• Governments, donors and implementers must anticipate factors such as geography, HIV prevalence or individual barriers to care and address those factors in programs that are codesigned with clients and community. This creates models for service delivery that serve diverse populations. All this necessarily involves investment in both lay and professional health workers for quality clinical care that includes psychosocial support.
• Governments and donors should expand and invest in DSD models for treatment, which include: six monthly refills, community ART groups, nurse-led community ART distribution points, door-to-door ART delivery and there are many more!
• The field must also use these models to guide efforts to develop DSD for PrEP and HIV prevention. These include conducting online risk assessments and follow-up consultations, providing multi-month refills for continuing clients, peer drop-offs and courier delivery of PrEP refills, to name a few.
• It’s time to seize opportunities for integration with other essential services such as: sexual reproductive health and rights (as recently highlighted in a new report from UNAIDS and WHO), interventions for gender-based violence (GBV), and the response to COVID-19. This requires an enabling policy environment and robust program monitoring and evaluation.
• Human rights should never be compromised during the COVID-19 pandemic. Governments must find ways to deliver both COVID-19 and HIV programs within a human rights framework.

AVAC and our partners are leading the charge on DSD advocacy and on identifying where COVID-19 is impacting HIV service delivery. Along with other HIV advocates, we have recommended people living with HIV (PLHIV) receive three to six month refills of ARVs during lockdown. Georgetown University’s HIV Policy Lab has been writing about the need for these multi-month dispensing strategies and policies that support them. COMPASS advocacy partners in Malawi, Tanzania and Zimbabwe have engaged with their respective ministries of health and identified that staffing and supply shortages in ministries and among implementers are making it difficult or impossible to meet the recommendation. Advocates are continuing to follow up with ministries, implementers and funders to find ways to make DSD work during this time.

We are urgently working with TB, SRHR and other health advocates locally and globally to ensure that people receive the care, treatment and prevention they need for all aspects of their health. It isn’t an easy task. The effort requires collaborations and investment at a scale never before seen in global health. But there is no other choice. This is the only way.

This 10-week interactive and online course will help researchers and clinical trial stakeholder to apply the Good Participatory Practice (GPP) Guidelines in their unique settings. In this unprecedented time, sustaining effective partnerships is more crucial than ever before. This course provides a personalized learning experience, global knowledge, tools to advance GPP implementation in diverse contexts and access to GPP experts and professional networks. For more information, send an email to gpponlinecourse@avac.org.

The course starts runs from June 22 to August 28, 2020. Enroll now at engage.avac.org.

Black Lives Matter.

The Black lives of AVAC’s staff, partners and friends matter. The Black lives of those who live near our office in Harlem matter. The Black lives of those on the streets across the United States and around the world calling for justice and equity matter. It’s more important than ever to say these fundamental truths.

Since AVAC’s founding 25 years ago, our focus has been advocating for solutions to HIV, a virus that disproportionately affects Black and Brown people around the world. In 2020, we have widened our focus to advocate for an equitable response to COVID-19, another virus that is disproportionately devastating Black and Brown communities in the US and – increasingly – around the world.

We are HIV and global health advocates and activists, and our work is fundamentally about social justice and human rights. In the United States, police brutality is a moral, ethical and public health crisis that must be addressed by every one of us.

We can’t be silent. We won’t be silent. We join the call for true leadership from our government, for an end to police brutality and for justice and equity that addresses the systemic racism in the United States. We know we can’t address HIV or COVID-19 without addressing this insidious epidemic that also attacks communities of color, and we are committed to working with partners and allies to address it.

The AVAC team stands in solidarity with the families of Ahmaud Arbery, George Floyd, Tony McDade, Breonna Taylor, and the thousands of others whose names we know and those whose names we don’t know, who have lost their lives and opportunities to the epidemic of racism. We stand in solidarity with those on the streets every day calling for justice.

As an organization, AVAC is committed to coming together to interrogate our own privilege and power and ensure we do better as allies and partners. We know it won’t be easy and we know we won’t always get it right, but we are committed to listening, responding and learning. And we commit to redoubling our work of advocating for equity, diversity and social justice as we continue to seek solutions to HIV and other public health crises.

The AVAC team is united in sorrow and anger at the inequities that are being laid bare in America today. We advocate every day for an equitable HIV response, but we know that we can’t stop there. We stand with those who are calling for a more just and equitable world.

In case you missed it, AVAC has a number of new resources to support our collective advocacy for HIV prevention research and an equitable, evidence-based response to COVID-19.

HIV Advocates Demand an Ethical Response to COVID-19

• To accelerate search for COVID-19 vaccine, look to HIV and act globally, this commentary in Devex by AVAC’s Mitchell Warren calls for vaccine development and a response to COVID-19 driven by public health, engaged communities and global collaboration, not nationalism.
• In a live chat with aidsmap, AVAC Fellow Winifred Ikilai makes the case for Good Participatory Practice in COVID-19 vaccine development and delivery.
• HIV Advocates Respond to the COVID-19 Crisis – On USAID’s blog, the CASPR Coalition writes about the role HIV advocates must play so that resources and networks empower communities responding to COVID-19.
• COVID-19, Yes but HIV Needs Attention Too – In this article in Malawi’s Times newspaper, 2019 AVAC Fellow Josephine Chinele, from the Pakachere Institute for Health and Development Communication, exhorts leaders to safeguard gains in HIV while tackling COVID-19.
• Ethical Conduct of SARS-CoV-2 Vaccine Challenge Studies – AVAC and TAG respond to the call for human challenge studies in vaccine research–The WHO Working Group has articulated important criteria for assessing a challenge study, but we believe that they left out the most important one: Until there is an approved treatment, a challenge trial with a potentially fatal and as-yet untreatable pathogen is unacceptable.
• How COVID-19 Must Transform US Global Health Strategy – Writing in The Hill, AVAC Executive Director Mitchell Warren and President of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria Chris Collins challenge us not just to survive this crisis but to seize this moment and begin work on a more sustainable future–one in which the next global pandemics land in a more prepared, more secure and healthier world.
• A look at the pipeline: COVID-19 diagnostics, therapeutics and a potential vaccine. This document also links to a number of additional resources tracking these developments.

Unprecedented focus on vaccine development for COVID-19 put a new perspective on HIV Vaccine Awareness Day (HVAD) on May 18.

There’s never been more at stake or more opportunity to build global capacity to ethically develop and deliver vaccines, which are essential to eventually end HIV and face future epidemics.

• HIV Vaccines: Are You Aware? – This op-ed placed in Zambia’s Daily Mail Limited 2020 AVAC Fellow Esnart Sikazindu spells out why continued investment in HIV vaccine research is essential.
• AVAC’s new report, Five “P”s to Watch: Platforms, process, partnerships, payers and participatory practices that drive vaccine development, connects key issues and lays out how HIV vaccine research is making the search for a COVID-19 vaccine faster, smarter and more inclusive.
• AVAC’s latest podcast episode of Px Pulse features leading voices from HIV vaccine and prevention research talking about the intersection of HIV and COVID-19.
• Check out key messages on priorities and unique opportunities for vaccine advocacy for HIV, COVID-19 and future epidemics.

This post first appeared on USAID.gov. For more information on COVID-19, please consult our COVID-19 and HIV Resources page, which includes a comprehensive set of information and advocacy Resources for Advocates. Daisy Ouya is AVAC’s Communications Advisor.

The COVID-19 pandemic demands that everyone apply their skills, resources and networks to empower communities and ease collective suffering.

The USAID-supported Coalition to Accelerate and Support Prevention Research (CASPR) was created in 2016 to expand robust advocacy efforts around HIV prevention research. We are a network of research-literate HIV prevention advocates working globally with an emphasis on sub-Saharan Africa. The Coalition places a special focus on literacy in infectious diseases, clinical research and trial design, through its long-standing partnerships with local and regional civil society, researchers, national governments, normative agencies and the media.

Although HIV and SARS-CoV-2 (the virus that causes COVID-19) have many important differences, such as mode of transmission, infectivity, case-fatality and global distribution, this emerging pandemic emergency has given rise to many déjà vu moments where the well-honed HIV advocacy skills of CASPR members can be applied. And we are rising to the challenge.

Using virtual gatherings, public statements, media trainings, blogs, podcasts and social media, the Coalition is actively debunking misconceptions, conspiracy theories, anti-vaccine and anti-research narratives. We are empowering our communities to recognize the myths and outright disinformation about COVID-19 and about research, and actively promoting the only evidence-based prevention options currently known: physical distancing, handwashing, and the proper use of face masks.

We are educating communities on efforts toward vaccines and therapeutics, the research and development process, the ethical principles that govern clinical research globally, and the strengths and limitations of mathematical modelling as it applies to the COVID-19 and HIV epidemiology. In parallel, we are highlighting the importance of global cooperation in COVID-19 research through initiatives such as the COVID-19 Clinical Research Coalition. A recent global webinar and new podcast examine the huge contributions of HIV vaccine research and partnerships to the current search for COVID-19 vaccines and therapies, but also how current COVID-19 research is likely to contribute to HIV vaccine research.

Ethical research for solutions to COVID-19 requires that communities be fully engaged. The UNAIDS/AVAC Good Participatory Practice Guidelines for biomedical HIV prevention trials, the World Health Organization’s Good Participatory Practice for Trials of Emerging Pathogens (GPP-EP), and the UNAIDS/WHO Ethical Guidelines for Biomedical Research Involving Human Subjects are key references in human rights-based research conduct. Ethical considerations also demand a swift and equitable delivery of testing, treatment and prevention options, prioritizing those most at risk.

While recognizing the global havoc wreaked by the novel coronavirus pandemic, we are tracking and condemning the proliferation of dehumanizing and stigmatizing language. We are advocating strongly against branding people ‘COVID suspects’, ‘super-spreaders’ or worse. Our recent webinars with journalists in Africa and India discussed journalists’ safety in COVID-19 reporting, as well as the role and power of language in the response.

Renowned African researchers and advocates have featured on webinars we have hosted to unpack the effect of COVID-19 on HIV prevention clinical trials and health services in Africa. Several CASPR members have been asked to contribute to radio and television panels in our respective countries to discuss the pandemic and its intersection with HIV.

We are pushing for an age- and gender-responsive, human rights-based approach to COVID-19—like the decades of HIV activism that has shaped the response to HIV & AIDS. Our goal is to ensure that equity and our shared humanity is at the center of the response at all levels and confers special protection for those likely to suffer the greatest socio-economic shocks and deleterious health impacts from the COVID-19 pandemic.

It is crucial that we renew our advocacy to strengthen health systems and to expand African domestic funding for health, as countries urgently mobilize their healthcare resources to deal with the COVID-19 crisis.

As for HIV, we are tracking COVID-19 research and pipeline of products and documenting the profound effects the COVID-19 crisis is having on promising HIV efficacy trials in communities. We stand with fellow advocates and researchers who have identified the need for an efficient resumption of HIV prevention research as soon as it is safe to do so.

This HIV Vaccine Awareness Day, we celebrate and thank the clinical trial participants, health workers, researchers and funders coming together to develop durable public health solutions for humanity.

In this time of COVID-19, new information and new questions arise daily with implications for global health advocacy and for the HIV response at large. In the midst of this, HIV research has taken some major steps forward as well. AVAC has produced a number resources to keep you informed and guide your advocacy on all these issues.

In the Headlines: Research on long-acting PrEP for HIV prevention

AVAC’s Statement on HPTN 083—HPTN 083 stopped the placebo arm of this trial two years early, after a rescheduled review of the data showed the product was at least as good as oral PrEP. AVAC’s statement explains the trial, the findings and talks about what’s next. For a deeper dive into the trial design check out our infographic or the Px Pulse episode on the issue. You can also join an HPTN webinar on the results tomorrow, May 22nd, at 10:30 ET.

COVID-19: Research standing on the shoulders of HIV

• AVAC’s new report, Five “P”s to Watch: Platforms, process, partnerships, payers and participatory practices that drive vaccine development, connects the key issues and lays out how HIV vaccine research is making the search for a COVID-19 vaccine faster, smarter and more inclusive.
• Read HIV Advocates Respond to the COVID-19 Crises, a blog by AVACer Daisy Ouya writing on behalf of the USAID-supported Coalition to Accelerate and Support Prevention Research (CASPR). The blog looks at how the Coalition has adapted skills, resources and networks to empower communities and ease collective suffering.
• Our webinar, The Power–and Pitfalls–of Modeling for COVID-19 and HIV, discusses current COVID-19 models and the benefits and limitations of mathematical models as they apply to both COVID-19 and HIV prevention.
• Listen to a webinar on the COVID-19 vaccine pipeline with Science Magazine’s Jon Cohen. Cohen talks about the rapidly growing pipeline, the direct links to HIV research and the risks of benefits of speeding up the process, including the thorny issue of human challenge trials. While the WHO issued criteria for assessing a challenge study, AVAC and TAG issued a joint statement outlining concerns and necessary prerequesites to consider going forward this way.
• In case you missed it, the latest episode of Px Pulse features a detailed look at the partnerships and innovation that can propel ethical research on HIV and COVID-19, and a status report on how ongoing HIV prevention trials are adapting during the COVID-19 pandemic.

Expanding Our Work: Integrating HIV prevention with sexual and reproductive health

AVAC has long promoted a research agenda centered on women, but both the ECHO trial results and the rollout of PrEP have highlighted the urgent need to bring proven interventions for both HIV and sexual and reproductive health to the women who need them. In our blog Programs, Products, Services and Users: HIV & SRH integration is the future of prevention we outline our expanding advocacy to advance HIV/SRH integration, introduce a suite of new resources and our new page on avac.org devoted to HIV/SRH integration.